Advances in Research on Congenital and Hereditary Intestinal Diseases: From Molecular Mechanisms to Precision Medicine

Recommend:

This article systematically reviews the molecular genetic basis, pathogenic mechanisms, and frontiers of precision medicine for congenital and hereditary intestinal diseases (such as Familial Adenomatous Polyposis, Peutz-Jeghers Syndrome, Lynch Syndrome, Hirschsprung's Disease, Congenital Short Bowel Syndrome, and Cystic Fibrosis). It covers cross-disease research hotspots including gene-environment interactions, organoid models, immune microenvironment, and remodeling of metabolism and microbiome. The article also outlines future directions such as gene therapy, targeted drugs, and immune prevention, providing important theoretical support for translational medicine and personalized treatment.

 

Literature Overview
This article, 'Advances in Research on Congenital and Hereditary Intestinal Diseases: From Molecular Mechanisms to Precision Medicine,' published in the journal 'Intractable & Rare Diseases Research,' summarizes the molecular genetic mechanisms and pathogenic pathways of congenital and hereditary intestinal diseases. It analyzes cutting-edge research directions such as organoid models, microbiome regulation, and immune microenvironment intervention, and discusses the commonalities and differences in their clinical management. The article emphasizes the future application of multi-omics integration and artificial intelligence in precision medicine, offering new research perspectives for gene therapy, vaccine development, and regenerative medicine.

Background Knowledge
Congenital and hereditary intestinal diseases are important rare diseases affecting gastrointestinal health, including Familial Adenomatous Polyposis (FAP), Peutz-Jeghers Syndrome (PJS), Lynch Syndrome (LS), Hirschsprung's Disease (HSCR), Congenital Short Bowel Syndrome (SBS), and Cystic Fibrosis (CF). These diseases are typically caused by mutations in key genes (such as APC, STK11, MLH1, MSH2, RET, CFTR), with pathogenic mechanisms involving dysregulation of signaling pathways like Wnt/β-catenin, AMPK/mTOR, and DNA mismatch repair systems. In recent years, technologies such as organoid models, genome editing, microbiome analysis, and immune checkpoint inhibitors have advanced the study of disease mechanisms and personalized therapies. However, high diagnostic heterogeneity, limited treatment options, and long-term complications remain clinical challenges. This article systematically summarizes the molecular mechanisms, research hotspots, and future directions of these diseases, providing theoretical support for related research and clinical translation.

 

A practical tool for quickly mapping DNA or RNA sequences to the genome.

Learn More

 

Research Methods and Experiments
This review systematically summarizes the molecular mechanisms, pathogenic pathways, clinical manifestations, diagnostic methods, treatment strategies, and research progress of six congenital or hereditary intestinal diseases: FAP, PJS, LS, HSCR, SBS, and CF. The study integrates genomics, epigenetics, metabolomics, and microbiome data to analyze common mechanisms across these diseases, such as immune microenvironment remodeling, microbiome alterations, and metabolic reprogramming. Additionally, the article introduces the application of advanced technologies like organoid models, immune checkpoint inhibitors, gene therapy, and microbiome engineering in disease research and treatment.

Key Conclusions and Perspectives

• Familial Adenomatous Polyposis (FAP) is caused by APC gene mutations, leading to constitutive activation of the Wnt/β-catenin pathway. Studies show early metabolic reprogramming and clonal evolution in intestinal epithelium, suggesting a field effect in intestinal carcinogenesis.
• Peutz-Jeghers Syndrome (PJS) is caused by STK11/LKB1 mutations, affecting AMPK/mTOR signaling and cell polarity. Dysbiosis (enrichment of Veillonellaceae, reduction of SCFAs) is negatively correlated with polyp burden.
• Lynch Syndrome (LS) is associated with mutations in DNA mismatch repair genes (e.g., MLH1, MSH2), leading to MSI-H and widespread epigenetic changes. Specific gut microbes (e.g., pks+ E. coli) have been found to promote tumorigenesis.
• Hirschsprung's Disease (HSCR) is linked to RET gene mutations, which affect the migration of enteric neural crest cells. Research reveals that SMYD2 regulates m6A methylation via METTL3 and plays a role in disease pathogenesis.
• Congenital Short Bowel Syndrome (SBS) is associated with mutations in FOXF1, CLMP, and FLNA. Studies show that intestinal organoid transplantation can restore absorptive function, offering new insights for regenerative medicine.
• Cystic Fibrosis (CF) is caused by CFTR gene mutations that impair chloride ion channel function. Organoid models are shown to be useful for personalized drug testing (e.g., FIS assay), and reveal the relationship between intestinal inflammation and microbiome alterations.
• The study emphasizes future directions such as multi-omics integration, artificial intelligence, microbiome engineering, immune prevention, and gene editing, and proposes a precision medicine roadmap from genetic diagnosis to personalized therapy validation.

Significance and Future Perspectives
This study provides a systematic review of the mechanisms, clinical management, and new therapeutic developments for congenital and hereditary intestinal diseases. It emphasizes that future research should integrate multi-omics data, promote AI-assisted precision medicine, develop microbiome engineering and immune prevention strategies, and explore in vivo delivery of gene editing. Additionally, the study proposes using organoid models as a core platform for drug screening and personalized interventions, offering important support for clinical translation.

 

Input a gene to view its associated signaling pathways and known upstream/downstream molecules.

Learn More

 

Conclusion
In recent years, research on congenital and hereditary intestinal diseases has shifted from single-gene models to a systems biology framework, integrating immune, metabolic, and microbiome networks across multiple layers, significantly enhancing the understanding of phenotypic complexity. The comprehension of disease mechanisms has expanded from localized intestinal pathology to multi-organ dynamic coupling and tumor microenvironment, revealing broader therapeutic windows. The integration of organoid models with artificial intelligence algorithms and high-throughput screening technologies is building new precision medicine platforms, offering experimental foundations for personalized therapies. Furthermore, the management of long-term complications from neonatal to adult stages has promoted the concept of 'lifelong care' in clinical practice. In the future, research and clinical approaches in this field will accelerate toward multi-omics integration, automated screening, intelligent interventions, and dynamic health prediction, bringing new breakthroughs to translational and personalized medicine.

 

Lichao Yang, Yu Wang, Lianwen Yuan, and Wei Tang. Advances in research on congenital and hereditary intestinal diseases: From molecular mechanisms to precision medicine. Intractable & Rare Diseases Research.